Affinivax ile ilgili hikayeler

• GlaxoSmithKline announced it will buy Boston-based biotech Affinivax in an acquisition worth up to $3.3 billion (€3bn) to bolster its vaccines business. The UK drugmaker will be paying $2.1bn up front with following payments up to $1.2bn if Affinivax’s new vaccine succeeds in trials. A step back: GSK sold its oncology business to Novartis while buying its vaccines business in 2014. The companies then proceeded to merge their consumer health units into a joint ventu...Devamını Oku

01 Haz 2022

• GlaxoSmithKline (GSK) , patentli yeni nesil aşılar üreten ABD merkezli biyoteknoloji şirketi Affinivax'ı 2,1 milyar dolara satın alacağını açıkladı. Şirket ilerleyen aşamalarda 1,2 milyar dolar daha ödeyebilir.

01 Haz 2022